Key result
Treatment of diabetic rats with a combination of rosiglitazone and losartan produced a more pronounced beneficial effect on measured parameters compared to diabetic, RGN-, and Los-treated groups.
Why the study?
Does the combination of rosiglitazone and losartan improve vascular reactivity and inflammatory/oxidative markers in diabetic rats?
RCT
Randomized
Does the combination of rosiglitazone and losartan improve vascular reactivity and inflammatory/oxidative markers in diabetic rats?
The combination of rosiglitazone and losartan synergistically improves vascular function, inflammation, and oxidative stress in a diabetic rat model.
Answers are grounded in this paper and cite their sources.
May attenuate vascular inflammation in diabetic rats; leaves open clinical translation of combination therapy.
Diabetes with vascular complication needs strict interventions to retard possible serious complications. This research estimated the possible interaction of rosiglitazone (RGN) with losartan (Los) in diabetic rats. Male Sprague-Dawley rats were randomly divided into nondiabetic rats, diabetic rats, and diabetic rats that received RGN, Los, or a combination of RGN and Los. Measurement of serum glucose, vascular adhesion molecule-1, interleukin-6, tumor necrosis factor-α, aortic lipid peroxide (malondialdehyde), glutathione, superoxide dismutase, and total nitrate/nitrite levels was done. Also, the effects of RGN on the relaxation created by acetylcholine and sodium nitroprusside, contraction of isolated aortic rings provoked by phenylephrine and angiotensin II were determined. Results revealed that RGN or Los had a vasodilating effect to variable degrees indicated by enhanced effects on both acetylcholine-induced relaxation and the antagonistic effect on angiotensin II and phenylephrine-stimulated contraction of diabetic aortas with significant amelioration in serum glucose, vascular adhesion molecule-1, interleukin-6, and tumor necrosis factor-α levels and aortic oxidant/antioxidant balance. Treatment of diabetic rats with a combination of RGN and Los produced a more pronounced effect on the measured parameters compared to the diabetic, RGN-, and Los-treated groups. These findings point out the beneficial effects of RGN and Los combination in diabetic rats.
No takes yet. Share an insight, caveat, or question.
Ateyya et al. (2017) conducted an RCT in Diabetes. Rosiglitazone and losartan combination vs. Nondiabetic rats, untreated diabetic rats, and diabetic rats treated with rosiglitazone or losartan alone was evaluated on Serum glucose, vascular adhesion molecule-1, interleukin-6, tumor necrosis factor-α levels, and aortic oxidant/antioxidant balance. Treatment of diabetic rats with a combination of rosiglitazone and losartan produced a more pronounced beneficial effect on measured parameters compared to diabetic, RGN-, and Los-treated groups.
Synapse has enriched 10 related papers. Consider them for comparative context: